World of DTC Marketing

JUNE 1, 2021

SUMMARY: The FDA is coming under intense pressure to approve Biogen’s Alzheimer’s drug, but Aaron S. ” For Biogen, the stakes are high as approval is likely to earn tens of millions, of to billions, in profits but is hope a reason to approve a drug over science? .” Biogen needs a new drug revenue badly.

Side effects 187

Side effects FDA Patients Doctors 187

World of DTC Marketing

SEPTEMBER 24, 2021

SUMMARY: If I were to ask you, “what type of company is Biogen?” Biogen has lost its way and is in desperate need of a corporate rebranding. This week two colleagues, who worked at Biogen, left the company because they knew that the ax was coming after the failure of Aduhelm. Biogen is in trouble.

Insurance 222

Insurance Pharma Doctors Physicians 222

World of DTC Marketing

SEPTEMBER 7, 2022

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. Biogen’s failure should be a warning to other pharma companies. Now Biogen is a shell of a company selling off assets to survive.

Pharma 210

Pharma Food and Drug Administration Marketing Prescription 210

European Pharmaceutical Review

DECEMBER 9, 2022

Biogen Inc. (US). Tag Copenhagen A/S (Denmark). Alnylam Pharmaceuticals, Inc. (US). ATDBio Ltd. ( Biolegio B.V. Netherlands). Biolytic Lab Performance Inc. (US). CSBIO (US). Danaher Corporation (US). Eton Bioscience, Inc. (US). Eurofins Scientific (Germany). Ionis Pharmaceuticals, Inc. (US). LGC Limited (UK).

Marketing 89

Marketing Pharmaceutical 89

pharmaphorum

JANUARY 9, 2023

Along with Zolgensma – which made its debut in 2019 – Biogen has had approval to market its antisense-based therapy Spinraza (nusinersen) since 2016, while Roche got a green light for its orally-administered therapy Evrysdi (risdiplam) in 2020. .

Side effects 106

Side effects Patients Management Marketing 106

World of DTC Marketing

JUNE 23, 2021

Alzheimer’s really is a devastating diagnosis, and if Biogen had actually produced a game-changing product to slow its worst symptoms, it would have an immeasurable impact on millions of lives. Not to mention the $56,000 annual price tag. What’s more, 40 percent of those subjects suffered side effects, including severe brain swelling.

FDA 218

FDA Side effects Physicians Patients 218

pharmaphorum

NOVEMBER 24, 2022

One issue has been the cost of the drug, with health technology assessment agency NICE in the UK and the ICER organisation in the US both concluding its price tag means it is not a cost-effective option for health systems. The post J&J builds case for antidepressant Spravato with head-to-head trial appeared first on.

Sales 52

Sales Patients Competition Marketing 52